What is the current CD160 Antibody market size?

The CD160 Antibody market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the CD160 Antibody market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the CD160 Antibody market?

Increasing research on immunotherapies and growing demand for CD160 Antibody in diagnostics drive the market.

What are the challenges facing the CD160 Antibody market?

High development costs and stringent regulatory frameworks pose significant challenges.

Which regions are the leaders in the CD160 Antibody market?

North America and Europe are the leading regions due to high research investments.

Who are the top companies in the CD160 Antibody market?

Leading companies include AbbVie, Amgen, and Bristol-Myers Squibb, driving innovation and growth.

What are the future opportunities in the CD160 Antibody market?

Emerging applications in cancer treatment and increasing adoption in developing regions offer future outlook opportunities.

How does technology impact the CD160 Antibody market?

Advances in antibody engineering and production technologies improve efficiency and reduce costs.

What is the regulatory landscape for the CD160 Antibody market?

Regulatory frameworks vary by region, with the FDA and EMA playing key roles in approving CD160 Antibody products.

What is the future outlook for the CD160 Antibody market size?

The market is expected to reach USD 2.5 billion by 2033, driven by increasing demand and growth.

CD160 Antibody Growth Opportunities & Strategic Forecast 2033

CD160 Antibody by Application (Flow Cytometry, ELISA, Western Blot, Immunoprecipitation, Immunofluorescence, Others), by Types (Monoclonal Antibody, Polyclonal Antibody), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

CD160 Antibody Market Size | CAGR 10.2 Forecast 2033

CD160 Antibody Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD160 Antibody Market Overview

The CD160 Antibody market refers to the global industry involved in the research, development, and distribution of CD160 antibodies, which are crucial in understanding the immune system and developing treatments for various diseases. The CD160 Antibody market size is estimated to be around $1.3 billion in 2025, with a growth outlook that is expected to drive the industry's expansion. As we look ahead to the market forecast for 2026-2033, the industry is poised for significant growth, driven by advancements in technology, increasing demand for personalized medicine, and rising investments in research and development. The industry expansion is expected to be fueled by the growing need for effective treatments for autoimmune diseases, cancer, and infectious diseases.

Loading chart…

The CD160 Antibody market is expected to grow at a CAGR of around 10% during the forecast period, driven by macro drivers such as the increasing prevalence of autoimmune diseases, rising demand for personalized medicine, and advancements in technology. Key forces shaping the industry include technology shifts, such as the development of new antibody engineering technologies, regulations, such as the increasing scrutiny of antibody manufacturing processes, and competitive intensity, driven by the entry of new players in the market. The largest region in the CD160 Antibody market is expected to be North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the growing demand for CD160 antibodies in countries such as China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; LifeSpan BioSciences, Inc.; BioLegend; Thermo Fisher Scientific; Abcam; Bio-Techne; MyBiosource, Inc.; Merck KGaA; Bio-Rad Laboratories, Inc.; Arigo Biolaboratories Corp.; GeneTex, Inc.; Boster Biological Technology; Creative Diagnostics; OriGene Technologies, Inc.; Elabscience Biotechnology Inc.; Assay Genie; Abbexa Ltd.; Miltenyi Biotec; Cepham Life Sciences; ProSci Incorporated; CLOUD-CLONE CORP.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The CD160 Antibody market is poised for significant growth, driven by various factors. The following sections outline the key dynamics influencing the market's trajectory.

Growth Drivers2 items

Increasing research on immunotherapies and targeted therapies is driving the demand for CD160 Antibody market, with a growing focus on cancer treatments and autoimmune diseases.

Advancements in technology, such as high-throughput sequencing and gene editing, are expanding the applications of CD160 antibodies, contributing to the growth forecast of the market.

Restraints2 items

High development costs and stringent regulatory requirements are limiting the entry of new players in the CD160 Antibody market, thereby restricting its market size.

The complexity of manufacturing processes and the need for specialized equipment are also hindering the growth of the CD160 antibody market, affecting its overall growth forecast.

Opportunities2 items

The increasing adoption of precision medicine and personalized therapies is creating new opportunities for the CD160 Antibody market, with a growing demand for targeted treatments.

The expanding applications of CD160 antibodies in diagnostics and research are also driving the market's growth, with a rising focus on biomarker discovery and disease modeling.

Challenges2 items

The CD160 Antibody market faces challenges related to pricing and reimbursement, with varying levels of coverage and affordability affecting its adoption rates.

The intense competition among established players and new entrants is also affecting the market's dynamics, with a focus on innovation and differentiation to maintain market share.

Market Segmentation

Loading chart…

The CD160 Antibody market can be segmented based on Application, which refers to the specific use cases of CD160 Antibody in various industries. This segmentation category contributes to the overall CD160 Antibody market size by highlighting the different areas where the antibody is utilized, such as research and development, diagnostics, and therapeutics. Understanding the application segment is crucial for companies to identify potential opportunities and develop targeted strategies. The CD160 Antibody segmentation by application provides valuable insights into the market dynamics and trends.

Another significant segmentation category for the CD160 Antibody market is Types, which includes subtypes such as [object Object] and [object Object]. This category defines the different forms of CD160 Antibody available in the market, each with its unique characteristics and applications. The types segment contributes to the overall market size by catering to the diverse needs of customers and providing opportunities for companies to specialize in specific product offerings. Analyzing the types segment is essential for understanding the market taxonomy and identifying areas for growth and innovation.

CD160 Antibody Segmentation Breakdown10 items

Application

Flow Cytometry

ELISA

Western Blot

Immunoprecipitation

Immunofluorescence

Others

Types

Monoclonal Antibody

Polyclonal Antibody

Regional Insights

Loading chart…

The CD160 Antibody market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of CD160 Antibody in emerging economies. Key drivers for North America include investments in research and development, policies supporting innovation, and a mature ecosystem.

In Europe, key drivers include a strong infrastructure for research, a high level of awareness about CD160 Antibody, and demographics favorable to market growth. Asia Pacific is driven by government initiatives to promote research, a large and growing population, and increasing access to healthcare. Latin America and Middle East & Africa are expected to experience moderate growth, driven by expanding healthcare infrastructure and increasing demand for CD160 Antibody.

The regional forecast indicates that the CD160 Antibody market will continue to grow, driven by increasing demand and adoption across regions. Understanding the key drivers and trends in each region is crucial for stakeholders to make informed decisions and capitalize on emerging opportunities. As the market continues to evolve, it is essential to monitor regional trends and market growth to stay ahead of the competition.

Competitive Landscape

The CD160 Antibody market is moderately consolidated, with a mix of global players and local/regional companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The CD160 Antibody competitive landscape is characterized by high competition, with companies employing various strategies to differentiate themselves. Key competitive levers include pricing, product innovation, and distribution networks.

Companies in the CD160 Antibody market are adopting strategies such as M&A, partnerships, product launches, expansion, R&D, and localization to stay competitive. However, they face challenges such as margin pressure, compliance costs, and commoditization. To differentiate themselves, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies are notable players in the market:

Sino Biological, Inc. - regional expansion

LifeSpan BioSciences, Inc. - innovation pipeline

BioLegend - premium pricing

Thermo Fisher Scientific - vertical integration

Abcam - OEM tie-ups

Bio-Techne - local manufacturing

Key CD160 Antibody Companies21 items

Sino Biological, Inc.

LifeSpan BioSciences, Inc.

BioLegend

Thermo Fisher Scientific

Abcam

Bio-Techne

MyBiosource, Inc.

Merck KGaA

Bio-Rad Laboratories, Inc.

Arigo Biolaboratories Corp.

GeneTex, Inc.

Boster Biological Technology

Creative Diagnostics

OriGene Technologies, Inc.

Elabscience Biotechnology Inc.

Assay Genie

Abbexa Ltd.

Miltenyi Biotec

Cepham Life Sciences

ProSci Incorporated

CLOUD-CLONE CORP.

Market Ecosystem

The CD160 Antibody ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. This ecosystem can be broadly categorized into three segments: upstream, midstream, and downstream, with value being created and captured at each stage. Technology providers and suppliers form the upstream segment, while integrators and channels constitute the midstream segment, ultimately catering to the needs of end users in the downstream segment.

Raw material suppliers — providing essential components

OEMs / manufacturers — producing CD160 Antibody products

Technology providers — developing underlying technologies

System integrators / EPCs — integrating CD160 Antibody solutions

Distributors / channel partners — facilitating product distribution

Service providers / after-sales — offering post-sales support

End users / buyers — utilizing CD160 Antibody products

In the CD160 Antibody ecosystem, value flows through the interactions and relationships between these participants. Control points, such as regulatory approvals and standards, can influence the adoption of CD160 Antibody products. Dependency risks, including input constraints and approval timelines, can also impact the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can affect the dynamics of the ecosystem. A thorough value chain analysis is necessary to understand these complex interactions and identify potential bottlenecks.

Recent Industry Insights

The CD160 Antibody market has witnessed significant developments over the last 12-18 months, shaping the future of CD160 Antibody industry trends. Recent partnerships between key players have accelerated innovation, with a focus on enhancing product portfolios and expanding global reach. Notable mergers and acquisitions have also led to increased consolidation, allowing companies to strengthen their positions in the market.

Furthermore, the launch of novel products and technologies has improved the efficacy and safety of CD160 Antibody treatments. Regulatory changes have also played a crucial role in influencing the market, with updates to guidelines and standards aiming to ensure better patient outcomes. As the industry continues to evolve, it is essential to stay informed about the latest CD160 Antibody industry trends and developments to remain competitive.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the CD160 Antibody market outlook. The market exhibits moderate attractiveness due to its growing demand in research and therapeutic applications. Competitive intensity is relatively high, with several key players invested in the development of CD160 antibodies. The long-term outlook appears promising, driven by innovations in antibody engineering and their potential in treating various diseases.

The innovation landscape is characterized by ongoing research into the functional properties of CD160 antibodies, which is expected to fuel market growth. However, the demand–supply balance may be affected by regulatory factors and manufacturing constraints. Key risk factors include intellectual property disputes and fluctuations in market demand. Despite these challenges, the CD160 Antibody market is poised for growth, offering opportunities for investors and industry stakeholders.

11 items

1. Executive Summary

2. CD160 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD160 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD160 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Flow Cytometry

6.1.2. ELISA

6.1.3. Western Blot

6.1.4. Immunoprecipitation

6.1.5. Immunofluorescence

6.1.6. Others

6.2. Global CD160 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal Antibody

6.2.2. Polyclonal Antibody

6.3. Global CD160 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD160 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD160 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global CD160 Antibody Market Competition by Key Manufacturers

8.1. Global CD160 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD160 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Sino Biological, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. LifeSpan BioSciences, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BioLegend

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Abcam

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Techne

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. MyBiosource, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Merck KGaA

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Bio-Rad Laboratories, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Arigo Biolaboratories Corp.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. GeneTex, Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Boster Biological Technology

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Creative Diagnostics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. OriGene Technologies, Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Elabscience Biotechnology Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Assay Genie

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Abbexa Ltd.

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Miltenyi Biotec

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Cepham Life Sciences

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. ProSci Incorporated

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. CLOUD-CLONE CORP.

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD160 Antibody Market

Figure 4: Global CD160 Antibody Market: Drivers

Figure 5: Global CD160 Antibody Market: Challenges

Figure 6: Global CD160 Antibody Market: Trends

Figure 7: Global CD160 Antibody Market: Opportunity

Figure 8: Global CD160 Antibody Market: Restraint

Figure 9: Global CD160 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global CD160 Antibody Market Value (USD Million) By Region

Figure 15: Global CD160 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global CD160 Antibody Market Value (USD Million) By Region

Figure 23: Global CD160 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

95 items

Table 1: Market Segmentation Analysis

Table 2: Global CD160 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global CD160 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global CD160 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global CD160 Antibody Market Value (USD Million) By Region

Table 10: Global CD160 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global CD160 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD160 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD160 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Sino Biological, Inc. Basic Information And Sales Area

Table 31: Sino Biological, Inc.. Products Portfolio

Table 32: LifeSpan BioSciences, Inc. Basic Information And Sales Area

Table 33: LifeSpan BioSciences, Inc.. Products Portfolio

Table 34: BioLegend Basic Information And Sales Area

Table 35: BioLegend. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Abcam Basic Information And Sales Area

Table 39: Abcam. Products Portfolio

Table 40: Bio-Techne Basic Information And Sales Area

Table 41: Bio-Techne. Products Portfolio

Table 42: MyBiosource, Inc. Basic Information And Sales Area

Table 43: MyBiosource, Inc.. Products Portfolio

Table 44: Merck KGaA Basic Information And Sales Area

Table 45: Merck KGaA. Products Portfolio

Table 46: Bio-Rad Laboratories, Inc. Basic Information And Sales Area

Table 47: Bio-Rad Laboratories, Inc.. Products Portfolio

Table 48: Arigo Biolaboratories Corp. Basic Information And Sales Area

Table 49: Arigo Biolaboratories Corp.. Products Portfolio

Table 50: GeneTex, Inc. Basic Information And Sales Area

Table 51: GeneTex, Inc.. Products Portfolio

Table 52: Boster Biological Technology Basic Information And Sales Area

Table 53: Boster Biological Technology. Products Portfolio

Table 54: Creative Diagnostics Basic Information And Sales Area

Table 55: Creative Diagnostics. Products Portfolio

Table 56: OriGene Technologies, Inc. Basic Information And Sales Area

Table 57: OriGene Technologies, Inc.. Products Portfolio

Table 58: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 59: Elabscience Biotechnology Inc.. Products Portfolio

Table 60: Assay Genie Basic Information And Sales Area

Table 61: Assay Genie. Products Portfolio

Table 62: Abbexa Ltd. Basic Information And Sales Area

Table 63: Abbexa Ltd.. Products Portfolio

Table 64: Miltenyi Biotec Basic Information And Sales Area

Table 65: Miltenyi Biotec. Products Portfolio

Table 66: Cepham Life Sciences Basic Information And Sales Area

Table 67: Cepham Life Sciences. Products Portfolio

Table 68: ProSci Incorporated Basic Information And Sales Area

Table 69: ProSci Incorporated. Products Portfolio

Table 70: CLOUD-CLONE CORP. Basic Information And Sales Area

Table 71: CLOUD-CLONE CORP.. Products Portfolio

Table 72: Global Market Value (USD Million) (2025-2032) By Application

Table 73: Global Market Share (%) By Application (2032)

Table 74: Global Market Value (USD Million) (2025-2032) By Types

Table 75: Global Market Share (%) By Types (2032)

Table 76: Global CD160 Antibody Market Value (USD Million) By Region

Table 77: Global CD160 Antibody Market Share (%) By Region (2025-2032)

Table 78: North America Market Value (USD Million) (2025-2032) By Country

Table 79: North America Market Value (USD Million) (2025-2032) By Application

Table 80: North America Market Value (USD Million) (2025-2032) By Types

Table 81: Europe Market Value (USD Million) (2025-2032) By Country

Table 82: Europe Market Value (USD Million) (2025-2032) By Application

Table 83: Europe Market Value (USD Million) (2025-2032) By Types

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 87: South America Market Value (USD Million) (2025-2032) By Country

Table 88: South America Market Value (USD Million) (2025-2032) By Application

Table 89: South America Market Value (USD Million) (2025-2032) By Types

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 93: Research Programs/Design For This Report

Table 94: Key Data Information From Secondary Sources

Table 95: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

CD160 Antibody Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.61 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sino Biological, Inc.; LifeSpan BioSciences, Inc.; BioLegend; Thermo Fisher Scientific; Abcam; Bio-Techne; MyBiosource, Inc.; Merck KGaA; Bio-Rad Laboratories, Inc.; Arigo Biolaboratories Corp.; GeneTex, Inc.; Boster Biological Technology; Creative Diagnostics; OriGene Technologies, Inc.; Elabscience Biotechnology Inc.; Assay Genie; Abbexa Ltd.; Miltenyi Biotec; Cepham Life Sciences; ProSci Incorporated; CLOUD-CLONE CORP.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options